BOULDER, COLORADO, August 7, 2014 – Siva Therapeutics has had a manuscript accepted for publication in the Journal of Nanomaterials. The forthcoming paper, entitled “Photothermal therapy using gold nanorods and near-infrared light in a murine melanoma model increases survival and decreases tumor volume” by Mary Popp and colleagues, describes Siva’s approach to photothermal monotherapy for melanoma, using the aggressive B16F10 mouse melanoma model. The study also describes the tissue and gel models used to develop and calibrate the photothermal therapy approach.
“We are happy to have our first peer-reviewed publication demonstrating the impressive capabilities of SivaRod™ monotherapy in a challenging rodent model,” said Len Pagliaro, PhD, CEO of Siva, “This work validates the ability of our approach to deliver potent and targeted heat, with minimal collateral damage. We are now focusing on using SivaRod™ therapy as part of combination therapies, and with targeted nanorods.”
A preprint of the publication can be found at: www.hindawi.com/journals/jnm/aip/450670/.
About Siva Therapeutics Inc
Siva Therapeutics Inc is developing photothermal cancer therapy which uses heat to irreversibly damage solid tumor tissue. The heat is delivered to tumors by infrared light that is absorbed by gold nanoparticles and re-emitted as heat. The size, shape, and surface chemistry of the particles target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Siva therapy promises to be extremely safe, effective, and competitive in cost relative to surgery, chemotherapy, and radiation for cancer treatment. For more information please visit: www.sivatherapeutics.com.
Media Contact: email@example.com.
To view a .pdf of this press release: Siva Therapeutics Publishes in the Journal of Nanomaterials